H3 Biomedicine and Selvita Reach First Research Milestone in Precision Cancer Medicines Collaboration
Companies Advance Multiple Co-discovery Programs for First-in-class Targets in Oncology
H3 Biomedicine Inc. and Selvita announced that they have achieved the first research milestone in their strategic collaboration to develop breakthrough precision medicines for cancers. The companies have validated the importance and druggability of a kinase target in a specific genetic context and have generated multiple novel chemical series against this target. The companies expect the first candidate molecule originating from the collaboration to move to IND-enabling studies in 2015.
H3 Biomedicine will provide a milestone to Selvita in consideration of Selvita’s achievement of the first research goal in the project. The companies are not disclosing the amount.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

EMBL spins the Sleeping Beauty transposase

Research points to a new treatment for pancreatic cancer
Twin study reveals epigenetic alterations of psychiatric disorders
Dalton Pharma Services Names New Sales and Marketing Manager
Cell-free protein production - New way to produce critical proteins for medicine and industry sidesteps use of live cells
Genes found linked to breast cancer drug resistance could guide future treatment choices
OneWorld Health and BioFocus DPI expand collaboration to develop new drugs for the treatment of childhood diarrheal diseases - BioFocus DPI to perform high-throughput screening
